1. Division of Onco‐cardiology, Hyogo cancer center, Akashi Japan ; 2. Division of Respiratory Medicine, Hyogo cancer center, Akashi Japan ; 3. Division of Health Sciences, Department of Nursing, Kobe Tokiwa University, Kobe Japan
Abstract:
A patient with lung cancer was administrated osimertinib. She developed symptomatic heart failure due to Takotsubo cardiomyopathy (TC). As her condition improved after discontinuing osimertinib, TC was thought to be caused by osimertinib. Reoccurrence of TC was seen after readministrating half dose of osimertinib.